Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Polyelectrolyte nanoparticles enable intracellular delivery of STING protein fragments for ovarian cancer immunotherapy.

Materials today. Bio·2026
Same author

DLL3 Expression in a Genotyped Cohort of Sporadic Medullary Thyroid Carcinomas.

The American journal of surgical pathology·2026
Same author

Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial.

Nature communications·2026
Same author

PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.

Nature communications·2026
Same author

First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Nov 23, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.8K

Targeting the mutant p53 secretome.

Kartik Sehgal1,2, David A Barbie1,2

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

The Journal of Clinical Investigation
|January 4, 2021
PubMed
Summary

Researchers identified a novel therapeutic target for lung adenocarcinoma by uncovering how mutant p53 proteins are secreted. Inhibiting GRASP55 suppressed tumor growth and metastasis, offering a new strategy against p53-deficient cancers.

More Related Videos

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.4K
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

11.3K

Related Experiment Videos

Last Updated: Nov 23, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.8K
Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.4K
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

11.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The tumor suppressor protein p53 is frequently mutated in cancer and remains a therapeutic challenge.
  • Understanding the mechanisms of mutant p53's role in cancer progression is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the mechanistic basis of the mutant p53 secretome in preclinical models of lung adenocarcinoma.
  • To identify novel therapeutic targets for TP53-deficient lung cancers.

Main Methods:

  • Investigated the role of microRNA-34a (miR-34a) in regulating protein secretion.
  • Examined the involvement of Golgi reassembly and stacking protein 55 kDa (GRASP55), basic leucine zipper nuclear factor 1, and myosin IIA in the secretion pathway.
  • Assessed the effects of GRASP55 inhibition in TP53-deficient lung adenocarcinoma models.

Main Results:

  • Discovered miR-34a as a regulator of a conventional protein secretion axis involving GRASP55, NF-Y, and myosin IIA.
  • Inhibition of GRASP55 suppressed the secretion of osteopontin and IGFBP2, which promote tumor growth.
  • Reduced tumor growth and metastasis in mice and patient-derived xenografts upon GRASP55 inhibition.

Conclusions:

  • The study reveals a novel secretion pathway regulated by miR-34a and involving GRASP55, crucial for mutant p53-driven lung adenocarcinoma.
  • Targeting GRASP55 presents a promising therapeutic strategy to counteract the protumorigenic effects of p53 loss in lung cancer.